←
Alí Duarte, MD1,798 posts
Alí Duarte, MD avatar

Alí Duarte, MD

@AliDuarteMD

Rheumatologist | Physician-scientist | Clinical informatician @MayoClinic | Director, Lupus Clinic | Lupus, LN & APS | AI in autoimmune diseases | 🇲🇽in🇺🇸

◷ Joined February 2018▧ 188 Photos and videos
Alí Duarte, MD avatar
Alí Duarte, MD@AliDuarteMD·Oct 11

Mayo Clinic Rheumatology just turned 100. Cortisone. A Nobel Prize. The LE cell. Generations of work that changed the field. A great symposium, alumni from near and far, and a packed dance floor with the people who make this division what it is. Here’s to the next 100. 🥂

Post attachmentPost attachmentPost attachmentPost attachment
Alí Duarte, MD avatar
Alí Duarte, MD@AliDuarteMD·Oct 6

5/ Very grateful to my coauthors, especially @ElHasbaniG for his indefatigable interest in APS (and surviving what felt like a million revisions!), and to Karen Schreiber, Ignasi Rodríguez-Pintó, Katrien Devreese & Danieli Andrade.

Alí Duarte, MD avatar
Alí Duarte, MD@AliDuarteMD·Oct 6

4/ Takeaway: APS is rare, but estimating how rare is difficult. We need longitudinal studies with consistent case definitions and better representation of diverse populations to understand its true burden.

Alí Duarte, MD avatar
Alí Duarte, MD@AliDuarteMD·Oct 6

3/ As APS classification criteria evolve, differences across studies or populations may reflect methodology and ascertainment as much as true epidemiology. Standardized definitions, laboratory linkage, and better population-based data are essential.

Alí Duarte, MD avatar
Alí Duarte, MD@AliDuarteMD·Oct 6

2/ Incidence and prevalence depend heavily on: • How APS is defined • Laboratory methods & antibody thresholds • Persistence requirements • Who gets tested • Data source: registries, EHRs, claims, or population-based surveillance

Alí Duarte, MD avatar
Alí Duarte, MD@AliDuarteMD·Oct 6

1/ How common is antiphospholipid syndrome (APS)? The answer is more complicated than it seems. In our new Nature Reviews Rheumatology review, we examine why defining the true epidemiologic burden of APS remains challenging. Full paper here👉: rdcu.be/M2Loes1Gqtia

Alí Duarte, MD avatar
Alí Duarte, MD@AliDuarteMD·Sep 29

5/ Clinical takeaway: Age should not lower our suspicion for SLE. New multisystem inflammatory disease in an older adult (including an older man) still warrants lupus in the differential. SLE presents across the life course.

Alí Duarte, MD avatar
Alí Duarte, MD@AliDuarteMD·Sep 29

4/ There were important demographic differences too. Among women, incidence was highest in Black women aged 20–39. Before age 20, rates were highest among Asian women; after 60, among American Indian/Alaska Native women.

Alí Duarte, MD avatar
Alí Duarte, MD@AliDuarteMD·Sep 29

3/ SLE also spans the extremes of age: • 10% were diagnosed before age 20 • 15.1% were diagnosed at age ≥60 Nearly 1 in 6 diagnoses occurred in older adults.

Alí Duarte, MD avatar
Alí Duarte, MD@AliDuarteMD·Sep 29

2/ The age pattern differed strikingly by sex: 👩 Women: incidence peaked at 30–39 years 👨 Men: incidence peaked at 60–69 years SLE in men has a much less “young-adult” pattern than we often assume.

Alí Duarte, MD avatar
Alí Duarte, MD@AliDuarteMD·Sep 29

1/ SLE is not confined to young women. Across 6 CDC-supported, population-based lupus registries (including LUMEN💡)—we examined how SLE incidence varies across demographic groups in diverse U.S. populations. acrjournals.onlinelibrary.wi…

Alí Duarte, MD avatar
Alí Duarte, MD@AliDuarteMD·Sep 22

5/ Clinical takeaway:In active nonrenal SLE, belimumab and anifrolumab have similar SRI-4 efficacy. Anifrolumab may offer greater BICLA response; belimumab has lower zoster risk.Choose based on phenotype, prior response, infection risk & patient preference.

Alí Duarte, MD avatar
Alí Duarte, MD@AliDuarteMD·Sep 22

4/ Safety may help break the tie. Serious adverse events and serious infections were broadly similar. The clearest difference was herpes zoster, which was more frequent with anifrolumab: OR 4.74 vs belimumab.

Alí Duarte, MD avatar
Alí Duarte, MD@AliDuarteMD·Sep 22

3/ But BICLA tells a somewhat different story. Anifrolumab was associated with higher odds of BICLA response vs belimumab: OR 1.56 (95% CI 1.10–2.21) This may suggest greater multidomain improvement, although the comparison is indirect and certainty was moderate.